{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:28:14Z","timestamp":1785940094066,"version":"3.56.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.tcm.2022.11.003","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T21:56:34Z","timestamp":1669931794000},"page":"128-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The role of statins in diabetic retinopathy"],"prefix":"10.1016","volume":"34","author":[{"given":"Oren","family":"Tomkins-Netzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Niederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6361-7305","authenticated-orcid":false,"given":"Susan","family":"Lightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tcm.2022.11.003_bib0001","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"Blindness","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"9733","key":"10.1016\/j.tcm.2022.11.003_bib0002","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Emerging Risk Factors","year":"2010","journal-title":"Lancet"},{"issue":"9326","key":"10.1016\/j.tcm.2022.11.003_bib0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"9435","key":"10.1016\/j.tcm.2022.11.003_bib0004","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2022.11.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174906","article-title":"Molecular targets of statins and their potential side effects: not all the glitter is gold","volume":"922","author":"Patel","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.tcm.2022.11.003_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.808712","article-title":"Undertreatment or overtreatment with statins: where are we?","volume":"9","author":"Garcia-Fernandez-Bravo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.tcm.2022.11.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26426","article-title":"Lipids, apolipoproteins, statins and ICH: a Mendelian randomization study","author":"Yu","year":"2022","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.tcm.2022.11.003_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/ph15020151","article-title":"Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer","volume":"15","author":"Morofuji","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.tcm.2022.11.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2840-12-S1-S3","article-title":"Statin diabetogenicity: guidance for clinicians","volume":"12","author":"Ray","year":"2013","journal-title":"Cardiovasc Diabetol"},{"issue":"21","key":"10.1016\/j.tcm.2022.11.003_bib0010","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"9716","key":"10.1016\/j.tcm.2022.11.003_bib0011","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.tcm.2022.11.003_bib0012","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1517\/14740338.2015.1096343","article-title":"Statins and their increased risk of inducing diabetes","volume":"14","author":"Agouridis","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"24","key":"10.1016\/j.tcm.2022.11.003_bib0013","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.tcm.2022.11.003_bib0014","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10456-007-9065-1","article-title":"Development of the retinal vasculature","volume":"10","author":"Fruttiger","year":"2007","journal-title":"Angiogenesis"},{"issue":"7\u201314","key":"10.1016\/j.tcm.2022.11.003_bib0015","article-title":"The pathology associated with diabetic retinopathy","volume":"139","author":"Lechner","year":"2017","journal-title":"Vision Res"},{"issue":"11","key":"10.1016\/j.tcm.2022.11.003_bib0016","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.tcm.2022.11.003_bib0017","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.eye.6701476","article-title":"Epidemiology of diabetic retinopathy and macular oedema: a systematic review","volume":"18","author":"Williams","year":"2004","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.tcm.2022.11.003_bib0018","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s001250051594","article-title":"UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis","volume":"44","author":"Stratton","year":"2001","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.tcm.2022.11.003_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","article-title":"Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group","volume":"34","author":"Amoaku","year":"2020","journal-title":"Eye (Lond)"},{"issue":"5 Suppl","key":"10.1016\/j.tcm.2022.11.003_bib0020","first-page":"786","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs\u2013an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.tcm.2022.11.003_bib0021","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00592-017-0974-1","article-title":"The English National Screening Programme for diabetic retinopathy 2003-2016","volume":"54","author":"Scanlon","year":"2017","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.tcm.2022.11.003_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.04.003","article-title":"Deep learning in ophthalmology: the technical and clinical considerations","volume":"72","author":"Ting","year":"2019","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"10.1016\/j.tcm.2022.11.003_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00125-017-4435-8","article-title":"Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond","volume":"61","author":"Hammes","year":"2018","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.tcm.2022.11.003_bib0024","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1167\/iovs.02-0648","article-title":"Diabetic retinopathy and serum lipoprotein subclasses in the DCCT\/EDIC cohort","volume":"45","author":"Lyons","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"14","key":"10.1016\/j.tcm.2022.11.003_bib0025","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJM199309303291410","article-title":"The diabetes control and complications trial. Implications for policy and practice","volume":"329","author":"Lasker","year":"1993","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.tcm.2022.11.003_bib0026","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.tcm.2022.11.003_bib0027","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archopht.1996.01100140281004","article-title":"Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22","volume":"114","author":"Chew","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.tcm.2022.11.003_bib0028","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0891-5849(91)90161-U","article-title":"Lipid peroxidation and retinopathy in streptozotocin-induced diabetes","volume":"11","author":"Armstrong","year":"1991","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.tcm.2022.11.003_bib0029","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0014-2999(00)00286-7","article-title":"Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid","volume":"398","author":"Obrosova","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.tcm.2022.11.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.R800085-JLR200","article-title":"Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways","volume":"50","author":"Goldberg","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.tcm.2022.11.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8746114","article-title":"Reverse cholesterol transport pathway and cholesterol efflux in diabetic retinopathy","volume":"2021","author":"Zhang","year":"2021","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.tcm.2022.11.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.visres.2017.04.010","article-title":"The role of dyslipidemia in diabetic retinopathy","volume":"139","author":"Hammer","year":"2017","journal-title":"Vision Res"},{"issue":"1","key":"10.1016\/j.tcm.2022.11.003_bib0033","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12944-019-0970-2","article-title":"Are blood lipids associated with microvascular complications among type 2 diabetes mellitus patients? A cross-sectional study in Shanghai, China","volume":"18","author":"Yang","year":"2019","journal-title":"Lipids Health Dis"},{"issue":"9500","key":"10.1016\/j.tcm.2022.11.003_bib0034","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"9600","key":"10.1016\/j.tcm.2022.11.003_bib0035","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.tcm.2022.11.003_bib0036","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.ophtha.2008.08.023","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes","volume":"115","author":"Klein","year":"2008","journal-title":"Ophthalmology"},{"issue":"9607","key":"10.1016\/j.tcm.2022.11.003_bib0037","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists","year":"2008","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.tcm.2022.11.003_bib0038","article-title":"Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)","volume":"100","author":"Board","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.tcm.2022.11.003_bib0039","unstructured":"Khatib R., Neely D. Summary of national guidance for lipid management for primary and secondary prevention of CVD. National Institute for Health and Care Excellence."},{"issue":"1","key":"10.1016\/j.tcm.2022.11.003_bib0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1210\/jc.2011-1679","article-title":"Clinical implications of the ACCORD trial","volume":"97","author":"Genuth","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.tcm.2022.11.003_bib0041","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","article-title":"The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"issue":"13)","key":"10.1016\/j.tcm.2022.11.003_bib0042","article-title":"Fenofibrate intervention and event lowering in diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]","volume":"4","author":"Scott","year":"2005","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.tcm.2022.11.003_bib0043","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.numecd.2017.05.004","article-title":"The PREDIMED trial, Mediterranean diet and health outcomes: how strong is the evidence?","volume":"27","author":"Guasch-Ferre","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.tcm.2022.11.003_bib0044","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1194\/jlr.M045401","article-title":"Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes","volume":"55","author":"Fu","year":"2014","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.tcm.2022.11.003_bib0045","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-8587(14)70173-1","article-title":"Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study","volume":"2","author":"Nielsen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.tcm.2022.11.003_bib0046","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaophthalmol.2018.6399","article-title":"Association of statin therapy with prevention of vision-threatening diabetic retinopathy","volume":"137","author":"Kang","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.tcm.2022.11.003_bib0047","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/1120672120922444","article-title":"Statin reduces the incidence of diabetic retinopathy and its need for intervention: a systematic review and meta-analysis","volume":"31","author":"Pranata","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.tcm.2022.11.003_bib0048","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema","volume":"102","author":"Klein","year":"1995","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.tcm.2022.11.003_bib0049","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13300-017-0240-0","article-title":"The role of dyslipidemia control in the progression of diabetic retinopathy in patients with type 2 diabetes mellitus","volume":"8","author":"Chatziralli","year":"2017","journal-title":"Diabetes Ther"},{"issue":"8","key":"10.1016\/j.tcm.2022.11.003_bib0050","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0161-6420(91)32145-6","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate","volume":"98","author":"Klein","year":"1991","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.tcm.2022.11.003_bib0051","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/jamaophthalmol.2014.5108","article-title":"Serum lipids and proliferative diabetic retinopathy and macular edema in persons with long-term type 1 diabetes mellitus: the wisconsin epidemiologic study of diabetic retinopathy","volume":"133","author":"Klein","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"10.1016\/j.tcm.2022.11.003_bib0052","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.ophtha.2015.05.011","article-title":"Dyslipidemia and diabetic macular edema: a systematic review and meta-analysis","volume":"122","author":"Das","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.tcm.2022.11.003_bib0053","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/cvr\/cvab032","article-title":"Emerging views of statin pleiotropy and cholesterol lowering","volume":"118","author":"Yu","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10.1016\/j.tcm.2022.11.003_bib0054","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/aos.12363","article-title":"Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment","volume":"92","author":"Tuuminen","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.tcm.2022.11.003_bib0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3928\/15428877-20100430-04","article-title":"Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol","volume":"41","author":"Panagiotoglou","year":"2010","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"1","key":"10.1016\/j.tcm.2022.11.003_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8227(01)00341-2","article-title":"Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia","volume":"56","author":"Sen","year":"2002","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.tcm.2022.11.003_bib0057","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3126\/nepjoph.v4i1.5846","article-title":"Atorvastatin in clinically-significant macular edema in diabetics with a normal lipid profile","volume":"4","author":"Narang","year":"2012","journal-title":"Nepal J Ophthalmol"},{"issue":"1","key":"10.1016\/j.tcm.2022.11.003_bib0058","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12933-016-0486-2","article-title":"Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy","volume":"16","author":"Chung","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.tcm.2022.11.003_bib0059","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1111\/dom.13372","article-title":"Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: a real-world observational analysis of a health claims database","volume":"20","author":"Kawasaki","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"378\u2013384","key":"10.1016\/j.tcm.2022.11.003_bib0060","article-title":"Lipid-lowering medications are associated with lower risk of retinopathy and ophthalmic interventions among united states patients with diabetes","volume":"207","author":"Vail","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.tcm.2022.11.003_bib0061","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.oret.2017.05.010","article-title":"Diabetic retinopathy in patients with dyslipidemia: development and progression","volume":"2","author":"Jeng","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.tcm.2022.11.003_bib0062","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/pds.5426","article-title":"Statin use and the risk of progression to vision threatening diabetic retinopathy","volume":"31","author":"Meer","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173822001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173822001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:03:53Z","timestamp":1760936633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173822001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1050173822001414"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2022.11.003","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of statins in diabetic retinopathy","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2022.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}